摘要:
The present invention relates to a novel bidentate motif that is composed of two adjacent residues of tyrosine and serine which have been found to be involved in the binding of crucial cytoplasmic proteins which are involved in cell signalling pathways. In some cases, the cytoplasmic proteins are ubiquitous proteins involved in cell signalling pathways that may include mitogenesis, transformation and survival. The bidentate motif may have a sequence alignment N-X-X-Y- (X) 1-13-[R/K/H/Q]-[X/Psi] 2-3-S/T-X-P; Y- (X) 1-16-[R/K/H/Q]-[X/Psi] 2-3-S/T-X-P; or N-X-X-Y-[X]1-30-[R/K/Q/H]-[X]1-4-[S/T]-X-p wherein X is any residue, Y is tyrosine, S/T is serine or threonine and Y is a hydrophibic residue or an equivalent thereof. Preferably the residues are Tyr577 and Ser585 of the common ßc of the GM-CSF/IL-5/IL-3 receptor.
摘要:
The present invention relates to a binding motif and methods of regulating cell function which methods target a single amino acid residue preferably a Tyr in a binding motif equivalent to a motif of the common beta chain (ßc) of the GM-CSF/IL-3/IL-5 receptor. Preferably, the cell functions affect cell survival and proliferation in cells. The methods can be used for treatments of conditions relating to cell survival and proliferation and can be used to expand progenitor cells, for instance, for transplantation purposes.
摘要:
A method of isolating a monoclonal antibody capable of inhibiting any one of IL-3, GM-CSF and IL-5 binding to the common receptor beta c, or a monoclonal antibody capable of inhibiting the cytokines binding to a receptor analogous to beta c. The method includes the steps of immunising an animal with a cytokine receptor or portion of a cytokine containing the critical binding site which portion includes the extracellular domain 4 or analogous domain in the analogous common receptor or part thereof. Antibodies producing cells from the animal are then isolated and fused with a myeloma cell line and then screened for a cell line that produces an antibody of the desired type. A monoclonal antibody, or fragments thereof capable of inhibiting the binding of the cytokines IL-3, GM-CSF and IL-5 to the beta c receptor, and a hybridoma cell line producing the antibody are also claimed.